Figure 8. DFMO augments the efficacy of adoptive T cell therapy.

(A) Mice were s.c. injected with 10⁶ B16-SIY cells (5 mice per group). DFMO was administered as a 1% solution in drinking water starting 1 day after tumor injection. Mice fed with dH₂O without DFMO were used as controls. 7 days after tumor inoculation, activated SIY-specific 2C CD8⁺ T cells were i.v. injected into tumor-bearing mice. (B) Mice were s.c. injected with 10⁶ B16F10 cells (5 mice per group). DFMO was administered as a 1% solution in drinking water starting 7 day after tumor injection. Mice fed with dH₂O without DFMO were used as controls. Activated gp100-specific Pmel CD8⁺ T cells were i.v. injected into tumor-bearing mice on the same day. Tumor volumes were measured every 3 days. Data (mean ± SEM) are representative of 2 independent experiments. *, p< 0.05; **, p<0.01.